- Title
- Calcitriol loading before total parathyroidectomy with autotransplant in patients with end-stage kidney disease: does it prevent postoperative hypocalcaemia?
- Creator
- Ferreira, David; Vilayur, Eswari; Gao, Michael; Sankoorikal, Christy; Bendinelli, Cino
- Relation
- Internal Medicine Journal Vol. 49, Issue 7, p. 886-893
- Publisher Link
- http://dx.doi.org/10.1111/imj.14209
- Publisher
- John Wiley & Sons
- Resource Type
- journal article
- Date
- 2019
- Description
- Background: Hungry bone syndrome (HBS) is one of the most serious complications following parathyroidectomy for severe hyperparathyroidism. There is a lack of literature informing the treatment and risk factors for this condition and the ideal pre-operative strategy for prevention. Aims: The primary aims were to examine the incidence of HBS with pre-operative calcitriol loading for 10 days and to determine the risk factors for HBS. The secondary aims were to determine the rate of intravenous calcium replacement in those with HBS and to assess whether cinacalcet removal has increased rates of parathyroidectomy in the end-stage kidney disease population. Methods: We performed a retrospective study from 2011 to 2018 on 45 patients with end-stage kidney disease undergoing total parathyroidectomy with autotransplantation for severe hyperparathyroidism. This was based at the John Hunter and Newcastle Private Hospitals in New South Wales. Results: 28.3% of patients with calcitriol loading undergoing parathyroidectomy fulfilled criteria for HBS. Pre-operative variables that were associated with HBS were elevated parathyroid hormone (P = 0.028) and longer duration of renal replacement therapy (P = 0.033). Rates of total parathyroidectomy were higher after the removal of calcimimetics from the Pharmaceutical Benefits Scheme (P = 0.0024). Conclusions: HBS remains a common complication of parathyroidectomy, even with prolonged high-dose calcitriol loading. This emphasises the need for further trials investigating other targeted therapies, such as bisphosphonates, to prevent HBS. Those most at risk of HBS are patients with high bone turnover and prolonged renal replacement therapy.
- Subject
- calcimimetic agents; hyperparathyroidism; hypocalcaemia; kidney failure; chronic; parathyroidectomy; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1509105
- Identifier
- uon:56200
- Identifier
- ISSN:1444-0903
- Language
- eng
- Reviewed
- Hits: 81
- Visitors: 81
- Downloads: 0